Seongsik Kang Selected Research

Vitamin K

1/2022	Comorbidities and Antithrombotic Treatment Pattern in Patients With Atrial Fibrillation.
10/2021	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: A nationwide, population-based study in Korea.
1/2020	The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis.
8/2019	Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry.
12/2018	Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II.
1/2018	Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Seongsik Kang Research Topics

Disease

9	Atrial Fibrillation 01/2022 - 01/2018
5	Stroke (Strokes) 01/2022 - 12/2018
4	Hemorrhage 10/2021 - 08/2019
3	Embolism (Embolus) 10/2021 - 01/2020
2	Thromboembolism 01/2022 - 12/2018
1	Myocardial Infarction 01/2022
1	Peripheral Arterial Disease 01/2022
1	Hyperglycemia 05/2018
1	Ischemic Stroke 01/2018
1	Pain (Aches) 03/2013
1	Drug Overdose 03/2013
1	Hypotension (Low Blood Pressure) 03/2013
1	Respiratory Insufficiency (Respiratory Failure) 03/2013

Drug/Important Bio-Agent (IBA)

6	AnticoagulantsIBA 01/2022 - 01/2018
6	Vitamin K FDA Link 01/2022 - 01/2018
4	N(4)-oleylcytosine arabinosideIBA 01/2022 - 01/2018
3	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 01/2020
1	RivaroxabanIBA 01/2020
1	apixabanIBA 01/2020
1	Dabigatran FDA Link 01/2020
1	Anesthetics (Anesthetic Agents)IBA 05/2018
1	Flumazenil (Romazicon)FDA LinkGeneric 05/2018
1	Midazolam (Versed)FDA LinkGeneric 05/2018
1	BenzodiazepinesIBA 05/2018
1	TransglutaminasesIBA 05/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2018

Therapy/Procedure

6	Therapeutics 01/2022 - 03/2013
1	Percutaneous Coronary Intervention 09/2021
1	Intravitreal Injections 05/2018
1	Patient-Controlled Analgesia (Analgesia, Patient Controlled) 03/2013